Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models
The FASEB Journal · 2023
DOI: 10.1096/fj.202301122rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Ye Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Type 2, Insulins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Previous studies have revealed that membrane phospholipid composition controlled by lysophosphatidylcholine acyltransferase 3 (LPCAT3) is involved in the development of insulin resistance in type 2 diabetes. In this study, we aimed to investigate the therapeutic potential of targeting Lpcat3 in the treatment of insulin resistance in diabetic mouse models. Lpcat3 expression was suppressed in the whole body by antisense oligonucleotides (ASO) injection or in the liver by adeno‐associated virus (AAV)‐encoded Cre in high‐fat diet (HFD)‐induced and genetic ob/ob type 2 diabetic mouse models. Glucose tolerance test (GTT), insulin tolerance test (ITT), fasting blood glucose, and insulin levels were used to assess insulin sensitivity. Lipid levels in the liver and serum were measured. The expression of genes involved in de novo lipogenesis was analyzed by real‐time RT‐PCR. Metabolic rates were measured by indirect calorimetry using the Comprehensive Lab Animal Monitoring System (CLAMS). Our data demonstrate that acute knockout of hepatic Lpcat3 by AAV‐Cre improves both hyperglycemia and hypertriglyceridemia in HFD‐fed mice. Similarly, whole‐body ablation of Lpcat3 by ASO administration improves obesity and insulin resistance in both HFD‐fed and ob/ob mice. These findings demonstrate that targeting LPCAT3 could be a novel therapy for insulin resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Biochemistry and Molecular Biology, and Center for Cardiovascular Research, Saint Louis University, St. Louis, Missouri, USA.
- Ionis Pharmaceuticals, Carlsbad, California, USA.
- Division of Nutritional Sciences, College of Agricultural, Consumer and Environmental Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
ORCID-Profile: Bo Wang
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Tian, Y., Lu, W., Shi, R., McGuffee, R., Lee, R., Ford, D. A., & Wang, B. (2023). Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models. The FASEB Journal. https://doi.org/10.1096/fj.202301122rr
Vancouver
Tian Y, Lu W, Shi R, McGuffee R, Lee R, Ford DA, et al. Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models. The FASEB Journal. 2023. doi:10.1096/fj.202301122rr
BibTeX
@article{Tian2023,
author = {Tian, Ye and Lu, Wei and Shi, Ruicheng and McGuffee, Reagan and Lee, Richard and Ford, David A and Wang, Bo},
title = {Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202301122rr}
}
EUVIMED